GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Fuso Pharmaceutical Industries Ltd (TSE:4538) » Definitions » Piotroski F-Score

Fuso Pharmaceutical Industries (TSE:4538) Piotroski F-Score : 4 (As of Mar. 28, 2025)


View and export this data going back to 1989. Start your Free Trial

What is Fuso Pharmaceutical Industries Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuso Pharmaceutical Industries has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Fuso Pharmaceutical Industries's Piotroski F-Score or its related term are showing as below:

TSE:4538' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 4

During the past 13 years, the highest Piotroski F-Score of Fuso Pharmaceutical Industries was 8. The lowest was 2. And the median was 5.


Fuso Pharmaceutical Industries Piotroski F-Score Historical Data

The historical data trend for Fuso Pharmaceutical Industries's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fuso Pharmaceutical Industries Piotroski F-Score Chart

Fuso Pharmaceutical Industries Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 8.00 6.00 8.00 4.00

Fuso Pharmaceutical Industries Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 4.00 -

Competitive Comparison of Fuso Pharmaceutical Industries's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Fuso Pharmaceutical Industries's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuso Pharmaceutical Industries's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuso Pharmaceutical Industries's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Fuso Pharmaceutical Industries's Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 円1,377 Mil.
Cash Flow from Operations was 円627 Mil.
Revenue was 円55,406 Mil.
Gross Profit was 円13,838 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (72466 + 75802) / 2 = 円74134 Mil.
Total Assets at the begining of this year (Mar23) was 円72,466 Mil.
Long-Term Debt & Capital Lease Obligation was 円7,021 Mil.
Total Current Assets was 円44,947 Mil.
Total Current Liabilities was 円29,650 Mil.
Net Income was 円1,605 Mil.

Revenue was 円51,015 Mil.
Gross Profit was 円13,740 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (69334 + 72466) / 2 = 円70900 Mil.
Total Assets at the begining of last year (Mar22) was 円69,334 Mil.
Long-Term Debt & Capital Lease Obligation was 円5,747 Mil.
Total Current Assets was 円43,219 Mil.
Total Current Liabilities was 円28,474 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuso Pharmaceutical Industries's current Net Income (TTM) was 1,377. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Fuso Pharmaceutical Industries's current Cash Flow from Operations (TTM) was 627. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=1377/72466
=0.01900201

ROA (Last Year)=Net Income/Total Assets (Mar22)
=1605/69334
=0.02314882

Fuso Pharmaceutical Industries's return on assets of this year was 0.01900201. Fuso Pharmaceutical Industries's return on assets of last year was 0.02314882. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Fuso Pharmaceutical Industries's current Net Income (TTM) was 1,377. Fuso Pharmaceutical Industries's current Cash Flow from Operations (TTM) was 627. ==> 627 <= 1,377 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=7021/74134
=0.09470688

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=5747/70900
=0.08105783

Fuso Pharmaceutical Industries's gearing of this year was 0.09470688. Fuso Pharmaceutical Industries's gearing of last year was 0.08105783. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=44947/29650
=1.51591906

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=43219/28474
=1.51784084

Fuso Pharmaceutical Industries's current ratio of this year was 1.51591906. Fuso Pharmaceutical Industries's current ratio of last year was 1.51784084. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Fuso Pharmaceutical Industries's number of shares in issue this year was 8.611. Fuso Pharmaceutical Industries's number of shares in issue last year was 8.771. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=13838/55406
=0.24975634

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=13740/51015
=0.26933255

Fuso Pharmaceutical Industries's gross margin of this year was 0.24975634. Fuso Pharmaceutical Industries's gross margin of last year was 0.26933255. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=55406/72466
=0.76457925

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=51015/69334
=0.73578619

Fuso Pharmaceutical Industries's asset turnover of this year was 0.76457925. Fuso Pharmaceutical Industries's asset turnover of last year was 0.73578619. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+0+0+1+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Fuso Pharmaceutical Industries has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Fuso Pharmaceutical Industries  (TSE:4538) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Fuso Pharmaceutical Industries Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Fuso Pharmaceutical Industries's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Fuso Pharmaceutical Industries Business Description

Traded in Other Exchanges
N/A
Address
No. 10, No. 7-chome Doshomachi, Chuo-ku, OsaKa, JPN, 541-0045
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid.

Fuso Pharmaceutical Industries Headlines

No Headlines